Fetuin-A Characteristics during and after Pregnancy: Result from a Case Control Pilot Study

Objective. Fetuin-A has been associated with gestational diabetes mellitus (GDM). We investigated fetuin-A levels during and after pregnancy in women with GDM. Fetuin-A measurements were performed in 10 women with GDM and 10 age and body mass index (BMI) matched healthy pregnant women. All women underwent an oral glucose tolerance test (OGTT) in and 3 months after gestation. Results. Fasting fetuin-A correlated with BMI in women with former GDM (r = 0.90, P < 0.0001) but showed no association with parameters of glucose tolerance in women with GDM or post-GDM. GDM featured significantly lower insulin sensitivity and higher insulin and C-peptide secretion profiles compared to NGT during pregnancy (P < 0.05). Fasting and postprandial fetuin-A did not differ between groups, neither during nor after pregnancy. Conclusion. Fetuin-A is not influenced by glucose tolerance during or after pregnancy or acute glucose elevations following glucose ingestion in young women, but closely relates to BMI early postpartum.

[1]  G. Pacini,et al.  A Model-Based Method for Assessing Insulin Sensitivity From the Oral Glucose Tolerance Test. Diabetes Care 2001;24:539–548 , 2014, Diabetes Care.

[2]  G. Schernthaner,et al.  Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. , 2010, The Journal of clinical endocrinology and metabolism.

[3]  M. Fowler,et al.  Clinical Practice Recommendations , 2009, Clinical Diabetes.

[4]  T. Reinehr,et al.  Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. , 2008, The Journal of clinical endocrinology and metabolism.

[5]  Annemarie Koster,et al.  Fetuin-A and incident diabetes mellitus in older persons. , 2008, JAMA.

[6]  A. Tura,et al.  Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione , 2006, Diabetes, obesity & metabolism.

[7]  M. Shlipak,et al.  Association Between Human Fetuin-A and the Metabolic Syndrome: Data From the Heart and Soul Study , 2006, Circulation.

[8]  F. Schick,et al.  α2-Heremans-Schmid Glycoprotein/ Fetuin-A Is Associated With Insulin Resistance and Fat Accumulation in the Liver in Humans , 2006 .

[9]  A. Schwarz,et al.  The serum protein α2–Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification , 2003 .

[10]  L. Kalabay,et al.  Correlation of maternal serum fetuin/alpha2-HS-glycoprotein concentration with maternal insulin resistance and anthropometric parameters of neonates in normal pregnancy and gestational diabetes. , 2002, European journal of endocrinology.

[11]  K Thomaseth,et al.  Insulin and C-peptide secretion and kinetics in humans: direct and model-based measurements during OGTT. , 2001, American journal of physiology. Endocrinology and metabolism.

[12]  G. Grunberger,et al.  α2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor , 2000, Molecular and Cellular Endocrinology.

[13]  G. Pagès,et al.  Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity , 1989, Cell.

[14]  髙田 浩史.  High glucose induces transactivation of the α2-HS glycoprotein gene through the ERK1/2 signaling pathway , 2009 .